Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Pemazyre pemigatinib Cholangiocarcinoma Do not reimburse Complete
Bimzelx bimekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Tavalisse fostamatinib Chronic immune thrombocytopenia Do not reimburse Complete
Zemaira Alpha1-proteinase inhibitor (Human) Severe Alpha1-proteinase inhibitor deficiency Reimburse with clinical criteria and/or conditions Complete
Intrarosa prasterone Postmenopausal vulvovaginal atrophy Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib RET fusion-positive non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Qinlock ripretinib Gastrointestinal stromal tumours Reimburse with clinical criteria and/or conditions Complete
Osphena ospemifene Dyspareunia, vaginal dryness Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib atopic dermatitis Reimburse with clinical criteria and/or conditions Complete